NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $6.68 +0.26 (+3.97%) As of 03:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Embecta Stock (NASDAQ:EMBC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Embecta alerts:Sign Up Key Stats Today's Range$6.35▼$6.7450-Day Range$4.75▼$6.4552-Week Range$2.77▼$14.91Volume557,137 shsAverage Volume1.49 million shsMarket Capitalization$378.21 millionP/E Ratio4.50Dividend Yield0.60%Price Target$11.00Consensus RatingReduce Company Overview Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products. The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world. Embecta’s products are designed to support diabetes treatment and monitoring across a range of care settings, including home care and clinical environments. Embecta became an independent publicly traded company in April 2022 after being spun off from Becton, Dickinson and Company, where its business had operated as the Diabetes Care segment. The company is headquartered in Parsippany, New Jersey, and is led by Chief Executive Officer Devdatt Kurdikar.AI Generated. May Contain Errors. Read More Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreEMBC MarketRank™: 3.8070222104 of 5 starsEmbecta scored higher than 76% of companies evaluated by MarketBeat, and ranked 142nd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialEmbecta has a consensus price target of $11.00, representing about 66.0% upside from its current price of $6.63.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-4.35% Earnings GrowthEarnings for Embecta are expected to decrease by -4.35% in the coming year, from $1.84 to $1.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 4.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 4.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.59.Read more about Embecta's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.42% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 5.43.Change versus previous monthShort interest in Embecta has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldEmbecta has a dividend yield of 0.64%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 2.70%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 2.27% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. News and Social Media3.8 / 5News Sentiment1.02 News SentimentEmbecta has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Embecta this week, compared to 8 articles on an average week.Search Interest1 people have searched for EMBC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Embecta to their MarketBeat watchlist in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Embecta in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $297,197.00 in company stock, which represents 0.0792% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have bought 803.17% more of their company's stock than they have sold. Specifically, they have bought $334,200.00 in company stock and sold $37,003.00 in company stock.Percentage Held by Insiders1.30% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMBC Stock News HeadlinesEmbecta (EMBC)September 30, 2026 | es.investing.comEMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary DutySeptember 22, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 21 at 1:00 AM | Base Camp Trading (Ad)EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary DutySeptember 2, 2026 | globenewswire.comembecta to Participate in Investor EventsAugust 31, 2026 | globenewswire.comEmbecta Stock Dividends | NASDAQ:EMBC | BenzingaAugust 26, 2026 | benzinga.comThe Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical ProductsAugust 24, 2026 | seekingalpha.comEMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock DropAugust 18, 2026 | prnewswire.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $11.88 at the start of the year. Since then, EMBC shares have decreased by 44.2% and is now trading at $6.6250. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) released its earnings results on Friday, August, 7th. The company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.29. Embecta's revenue was down 8.1% on a year-over-year basis. Read the conference call transcript. Who are Embecta's major shareholders? Top institutional shareholders of Embecta include CWA Asset Management Group LLC (0.95%), SummerHaven Investment Management LLC (0.11%), GAMMA Investing LLC (0.02%) and Quadrant Capital Group LLC (0.02%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann, David F Melcher and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Becton, Dickinson and Company (BDX), NVIDIA (NVDA), AT&T (T), UnitedHealth Group (UNH), Qualcomm (QCOM), Chevron (CVX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/07/2026Record date for 9/15 Dividend8/27/2026Ex-Dividend for 9/15 Dividend8/27/2026Dividend Payable9/15/2026Today10/21/2026Next Earnings (Estimated)11/24/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EMBC's financial health is in the Green zone, according to TradeSmith. EMBC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Supplies Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,850Year Founded2022Price Target and Rating Average Price Target for Embecta$11.00 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+65.8%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$1.48 Trailing P/E Ratio4.48 Forward P/E Ratio3.61 P/E GrowthN/ANet Income$95.40 million Net Margins8.59% Pretax Margin12.27% Return on Equity-19.25% Return on Assets10.82% Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick Ratio1.17 Sales & Book Value Annual Sales$1.08 billion Price / Sales0.35 Cash Flow$4.28 per share Price / Cash Flow1.55 Book Value($11.12) per share Price / Book-0.60Miscellaneous Outstanding Shares56,660,000Free Float55,923,000Market Cap$375.94 million OptionableOptionable Beta0.84 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EMBC) was last updated on 10/21/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
